👉 The program targets the LptA protein that disrupts the lipopolysaccharide transport bridge in Gram-negative bacteria.
👨⚕️ The program, funded by CARB-X, has shown activity against Enterobacteriaceae strains resistant to beta-lactams and colistin.
💊 Basilea will acquire all program compounds, including intellectual property, and pay Spexis up to CHF2m.
⚖️ The transaction is subject to approval by the Western District Court of the Canton Basel-Landschaft.
Introduction:
Macrocycle library specialist, Spexis AG, has agreed to sell a preclinical antibiotics program to Basilea Pharmaceutica Ltd. The program targets the protein LptA, which selectively disrupts the lipopolysaccharide transport bridge in Gram-negative bacteria, resulting in the elimination of the bacteria. The program has shown efficacy in vitro and in vivo against multidrug-resistant Gram-negative bacterial pathogens.
- Basilea Pharmaceutica Ltd. is acquiring a preclinical antibiotics program from Spexis AG for CHF2m.
- The program targets the protein LptA, which selectively disrupts the lipopolysaccharide transport bridge in Gram-negative bacteria.
- The program has shown efficacy in vitro and in vivo against multidrug-resistant Gram-negative bacterial pathogens.
- The compounds derived from the program have been optimized using Spexis’ macrocycle platforms and methodologies.
- The transaction is subject to the approval of the Western District Court of the Canton Basel-Landschaft.
Conclusion:
Spexis AG has sold a preclinical antibiotics program to Basilea Pharmaceutica Ltd. The program targets the protein LptA and has shown efficacy against multidrug-resistant Gram-negative bacterial pathogens. The compounds derived from the program have been optimized using Spexis’ macrocycle platforms and methodologies, making them a novel class of antibiotics. The acquisition of this program by Basilea highlights the urgent need for new antibiotics against priority pathogens identified by the World Health Organization.
